Wall Street analysts predict that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will report earnings of ($0.61) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.94). The company is scheduled to issue its next quarterly earnings report on Monday, August 12th.
On average, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($6.13) per share for the current fiscal year, with EPS estimates ranging from ($6.86) to ($4.75). For the next fiscal year, analysts expect that the company will report earnings of ($3.19) per share, with EPS estimates ranging from ($3.84) to ($2.92). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Tcr2 Therapeutics.
Tcr2 Therapeutics (NASDAQ:TCRR) last announced its earnings results on Monday, May 13th. The company reported ($4.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($4.47).
Shares of NASDAQ TCRR traded down $0.11 during trading on Tuesday, reaching $12.76. The company had a trading volume of 10,820 shares, compared to its average volume of 39,813. Tcr2 Therapeutics has a 52 week low of $12.59 and a 52 week high of $25.47. The stock has a market cap of $311.22 million and a PE ratio of -0.13. The business’s 50 day moving average is $14.60.
A number of large investors have recently modified their holdings of the business. Laurion Capital Management LP bought a new stake in Tcr2 Therapeutics in the first quarter valued at approximately $417,000. Dean Capital Investments Management LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter valued at approximately $694,000. Redmile Group LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter valued at approximately $28,686,000. Finally, MPM Asset Management LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter valued at approximately $67,192,000. 33.26% of the stock is owned by hedge funds and other institutional investors.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Featured Story: What are the benefits of a portfolio tracker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.